Company intelligence / Profile preview
Wugen
- Ownership
- Private
- Employees
- ~200
- Development stage
- Other
Overview
Wugen’s lead program, WU-CART‑007, is an off-the-shelf allogeneic CD7-targeted CAR-T therapy that has shown clinically manageable safety and anti-leukemic activity in relapsed/refractory T‑ALL/LBL patients. Phase 2 data demonstrated high efficacy surpassing standard of care. The company has initiated a pivotal trial following positive results and received RMAT and PRIME designations to accelerate regulatory review. Additional programs include memory NK cell therapies in early clinical or preclinical development targeting AML and solid tumors.
- Therapeutic areas
- Oncology
- Modalities
- Allogeneic CAR-T cell therapiesMemory natural killer (NK) cell therapiesEngineered NK cellsMonoclonal antibody combinations (for solid tumors)
- Industry
- Biotech
Drug pipeline
15 assets14 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Wugen.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Wugen.